new
data
meeting
showcase
safety
efficacy
biogen
ms
portfolio
new
data
ongoing
phase
study
define
effectiveness
improved
gi
tolerability
vumerity
diroximel
fumarate
diroximel
fumarate
findings
evaluate
quality
life
benefits
associated
tysabri
natalizumab
compared
ocrevus
ocrelizumab
natalizumab
compared
ocrevus
ocrelizumab
additional
findings
report
positive
benefits
peginterferon
interferon
older
individuals
relapsing
multiple
sclerosis
cambridge
globe
newswire
biogen
nasdaq
biib
today
announced
new
data
underscoring
efficacy
safety
broad
portfolio
multiple
sclerosis
ms
therapies
data
presented
eighth
joint
meeting
americas
committee
treatment
research
multiple
sclerosis
european
committee
treatment
research
multiple
sclerosis
held
virtually
september
biogen
proud
commitment
addressing
urgent
challenges
facing
people
living
ms
said
maha
radhakrishnan
chief
medical
officer
biogen
data
presenting
highlight
improved
outcomes
broad
ms
portfolio
continued
provide
people
relapsing
forms
ms
regardless
treatment
journey
well
ongoing
investment
research
development
identify
potentially
effective
drug
new
phase
data
characterize
effectiveness
gi
tolerability
diroximel
fumarate
new
data
vumerity
phase
clinical
program
define
effectiveness
safety
profile
biogen
latest
oral
fumarate
therapy
findings
study
reinforce
clinically
meaningful
improvements
gastrointestinal
gi
tolerability
associated
vumerity
treatment
compared
dimethyl
fumarate
support
impact
quality
life
people
relapsing
study
participants
taking
vumerity
reported
lower
likelihood
experiencing
gi
symptoms
interfered
daily
activities
associated
missed
work
well
less
concomitant
medication
use
treat
gi
symptoms
exploratory
analysis
ongoing
study
assessed
effects
vumerity
brain
volume
change
clinical
measures
people
relapsing
ms
treated
two
years
separate
studies
shown
brain
volume
loss
may
associated
cognitive
impairment
physical
disability
reduced
quality
life
people
data
show
annual
rate
brain
volume
change
study
participants
treated
vumerity
two
years
similar
rate
observed
healthy
individuals
approximately
percent
people
treated
vumerity
remained
free
confirmed
disability
progression
around
percent
two
years
also
presented
meeting
final
data
phase
endorse
study
demonstrate
sustained
efficacy
safety
profile
tecfidera
patients
followed
years
data
separate
analyses
relapsing
ms
population
show
improved
outcomes
natalizumab
peginterferon
interferon
ms
paths
partners
advancing
technology
health
solutions
biogen
collaborating
leading
ms
centers
europe
generate
standardized
data
diverse
ms
patient
population
date
patients
enrolled
ms
paths
data
presented
treatment
setting
support
improved
outcomes
associated
tysabri
plegridy
avonex
results
separate
analyses
ms
paths
data
reveal
following
first
comparison
ms
paths
standardized
magnetic
resonance
imaging
mri
protocols
analyses
changes
brain
mri
occurring
mean
years
compared
natalizumab
treatment
extended
interval
dosing
eid
approved
dosing
analysis
reported
significant
differences
rates
new
lesions
lesion
volumes
brain
atrophy
differences
mri
scanners
acquisition
protocols
clinical
practice
made
comparisons
brain
mri
outcomes
challenging
multiple
studies
suggested
effectiveness
natalizumab
eid
similar
approved
biogen
continues
evaluate
efficacy
safety
tolerability
natalizumab
eid
prospective
nova
trial
recently
filed
regulatory
authorities
subcutaneous
dosing
formulation
approved
would
allow
options
tysabri
administration
treatment
tysabri
associated
greater
improvements
ocrelizumab
several
quality
life
domains
according
quality
life
neurological
disorders
assessment
subgroup
analysis
matched
patients
treated
tysabri
ocrevus
significant
improvement
observed
nine
domains
patients
treated
tysabri
four
domains
patients
treated
ocrevus
overall
annualized
rates
improvement
higher
tysabri
ocrevus
significant
differences
observed
three
domains
positive
affect
satisfaction
social
roles
activities
sleep
disturbance
clinical
outcomes
people
ms
aged
older
compared
indicate
plegridy
avonex
may
provide
treatment
benefits
two
years
age
groups
data
show
functional
improvements
processing
speed
test
pst
contrast
sensitivity
test
cst
one
year
age
groups
additionally
majority
participants
age
groups
remained
free
relapse
two
years
data
phase
study
supports
continued
development
treatment
ms
biogen
also
presented
data
phase
study
orally
active
selective
reversible
noncovalent
small
molecule
inhibitor
bruton
tyrosine
kinase
btk
data
evaluated
safety
tolerability
pharmacokinetics
pharmacodynamics
single
multiple
ascending
oral
doses
healthy
adult
participants
selective
btk
inhibition
may
beneficial
treatment
ms
preventing
myeloid
cell
activation
without
immune
cell
depletion
data
presentations
featured
note
poster
presentations
made
available
online
et
friday
september
improved
gi
tolerability
diroximel
fumarate
associated
clinically
meaningful
benefits
quality
life
compared
dimethyl
fumarate
poster
effects
diroximel
fumarate
brain
volume
change
disability
progression
adults
multiple
sclerosis
poster
safety
efficacy
patients
treated
dimethyl
fumarate
followed
years
final
results
endorse
platform
sunday
september
et
difference
radiologic
outcomes
natalizumab
patients
extended
interval
dosing
compared
standard
interval
dosing
ms
paths
poster
impact
natalizumab
quality
life
cohort
patients
multiple
sclerosis
results
ms
paths
poster
characteristics
clinical
outcomes
older
patients
ms
treated
peginterferon
intramuscular
interferon
ms
paths
poster
phase
study
bruton
tyrosine
kinase
btk
inhibitor
healthy
adult
participants
preliminary
results
poster
diroximel
fumarate
vumerity
oral
fumarate
distinct
chemical
structure
dimethyl
fumarate
approved
treatment
relapsing
forms
multiple
sclerosis
adults
include
clinically
isolated
syndrome
disease
active
secondary
progressive
disease
body
vumerity
rapidly
converts
monomethyl
fumarate
active
metabolite
dimethyl
fumarate
vumerity
contraindicated
patients
known
hypersensitivity
diroximel
fumarate
dimethyl
fumarate
excipients
vumerity
patients
taking
dimethyl
fumarate
serious
side
effects
vumerity
based
data
dimethyl
fumarate
active
metabolite
vumerity
include
anaphylaxis
angioedema
progressive
multifocal
leukoencephalopathy
rare
opportunistic
viral
infection
brain
associated
death
severe
disability
decrease
mean
lymphocyte
counts
first
year
treatment
herpes
zoster
serious
infections
liver
injury
flushing
common
adverse
events
obtained
using
data
dimethyl
fumarate
active
metabolite
vumerity
flushing
abdominal
pain
diarrhea
nausea
please
click
important
safety
information
full
prescribing
information
including
patient
information
vumerity
dimethyl
fumarate
tecfidera
treatment
relapsing
forms
multiple
sclerosis
ms
adults
prescribed
oral
medication
relapsing
ms
world
shown
reduce
rate
ms
relapses
slow
progression
disability
impact
number
ms
brain
lesions
demonstrating
safety
profile
people
relapsing
forms
tecfidera
approved
countries
patients
treated
representing
exposure
across
clinical
trial
use
patients
prescribed
tecfidera
patients
clinical
tecfidera
contraindicated
patients
known
hypersensitivity
dimethyl
fumarate
excipients
tecfidera
serious
side
effects
include
anaphylaxis
angioedema
cases
progressive
multifocal
leukoencephalopathy
rare
opportunistic
viral
infection
brain
associated
death
severe
disability
seen
tecfidera
patients
setting
prolonged
lymphopenia
although
role
lymphopenia
cases
uncertain
serious
side
effects
include
decrease
mean
lymphocyte
counts
first
year
treatment
herpes
zoster
serious
infections
liver
injury
flushing
clinical
trials
common
adverse
events
associated
tecfidera
flushing
abdominal
pain
diarrhea
nausea
please
click
important
safety
information
full
prescribing
information
including
patient
information
tecfidera
visit
respective
country
product
website
natalizumab
tysabri
relapsing
multiple
sclerosis
rms
treatment
indicated
relapsing
forms
ms
adults
proven
clinical
trials
slow
physical
disability
progression
reduce
formation
new
brain
lesions
cut
relapses
tysabri
approved
countries
people
worldwide
treated
tysabri
experience
based
clinical
trials
prescription
tysabri
increases
risk
progressive
multifocal
leukoencephalopathy
pml
rare
opportunistic
viral
infection
brain
associated
death
severe
disability
risk
factors
increase
risk
pml
presence
virus
antibodies
prior
immunosuppressant
use
longer
tysabri
treatment
duration
patients
three
risk
factors
highest
risk
developing
pml
initiating
continuing
treatment
tysabri
physicians
consider
whether
expected
benefit
tysabri
sufficient
offset
risk
tysabri
also
increases
risk
developing
encephalitis
meningitis
caused
herpes
simplex
varicella
zoster
viruses
serious
sometimes
fatal
cases
reported
setting
ms
patients
receiving
tysabri
clinically
significant
liver
injury
including
acute
liver
failure
requiring
transplant
also
reported
setting
serious
adverse
events
occurred
patients
include
hypersensitivity
reactions
anaphylaxis
infections
including
opportunistic
atypical
infections
please
click
important
safety
information
including
boxed
warning
full
prescribing
information
including
medication
guide
tysabri
visit
respective
country
product
website
peginterferon
plegridy
subcutaneous
pegylated
interferon
dosed
every
two
weeks
relapsing
forms
multiple
sclerosis
ms
adults
common
form
plegridy
currently
approved
countries
including
canada
australia
switzerland
across
european
union
nearly
people
worldwide
treated
plegridy
experience
based
prescription
biogen
continues
work
toward
making
plegridy
available
additional
countries
across
globe
efficacy
safety
plegridy
supported
one
largest
pivotal
studies
interferons
conducted
people
living
ms
clinical
studies
plegridy
proven
significantly
reduce
rate
ms
relapses
slow
progression
disability
reduce
number
ms
brain
lesions
demonstrating
safety
profile
patients
relapsing
forms
side
effects
reported
include
liver
problems
including
liver
failure
increases
liver
enzymes
depression
suicidal
thoughts
serious
allergic
reactions
cardiac
problems
including
congestive
heart
failure
autoimmune
disorders
decreases
white
blood
cell
platelet
counts
seizures
clinical
trials
common
adverse
events
associated
plegridy
injection
site
reactions
symptoms
list
adverse
events
found
full
plegridy
product
labeling
country
approved
please
click
important
safety
information
full
prescribing
information
including
medication
guide
plegridy
visit
respective
country
product
website
interferon
avonex
prescribed
relapsing
forms
ms
currently
approved
countries
people
worldwide
treated
avonex
million
experience
based
prescription
avonex
indicated
treatment
relapsing
forms
multiple
sclerosis
ms
include
clinically
isolated
syndrome
disease
active
secondary
progressive
disease
adults
symptoms
depression
suicidal
ideation
psychosis
cases
suicide
reported
increased
frequency
patients
receiving
avonex
severe
hepatic
injury
including
cases
hepatic
failure
reported
rarely
patients
rare
cases
anaphylaxis
reported
beta
interferons
known
direct
cardiac
toxicity
cases
congestive
heart
failure
cardiomyopathy
cardiomyopathy
congestive
heart
failure
reported
patients
without
known
predisposition
decreased
peripheral
blood
counts
reported
postmarketing
experience
seizures
reported
patients
using
avonex
including
patients
prior
history
seizure
autoimmune
disorders
multiple
target
organs
reported
routine
periodic
blood
chemistry
hematology
liver
function
thyroid
function
tests
recommended
please
click
important
safety
information
full
prescribing
information
including
medication
guide
avonex
visit
respective
country
product
website
biogen
biogen
mission
clear
pioneers
neuroscience
biogen
discovers
develops
delivers
worldwide
innovative
therapies
people
living
serious
neurological
neurodegenerative
diseases
well
related
therapeutic
adjacencies
one
world
first
global
biotechnology
companies
biogen
founded
charles
weissmann
heinz
schaller
kenneth
murray
nobel
prize
winners
walter
gilbert
phillip
sharp
today
biogen
leading
portfolio
medicines
treat
multiple
sclerosis
introduced
first
approved
treatment
spinal
muscular
atrophy
commercializes
biosimilars
advanced
biologics
focused
advancing
research
programs
multiple
sclerosis
neuroimmunology
alzheimer
disease
dementia
neuromuscular
disorders
movement
disorders
ophthalmology
immunology
neurocognitive
disorders
acute
neurology
pain
routinely
post
information
may
important
investors
website
learn
please
visit
follow
us
social
media
twitter
linkedin
facebook
youtube
biogen
safe
harbor
news
release
contains
statements
including
statements
made
pursuant
safe
harbor
provisions
private
securities
litigation
reform
act
relating
potential
benefits
safety
efficacy
vumerity
tecfidera
tysabri
plegridy
results
certain
data
results
study
phase
endorse
study
phase
study
identification
treatment
ms
research
development
program
treatment
ms
potential
regulatory
discussions
submissions
approvals
timing
thereof
potential
biogen
commercial
business
including
vumerity
tecfidera
tysabri
plegridy
risks
uncertainties
associated
drug
development
commercialization
statements
may
identified
words
aim
anticipate
believe
could
estimate
expect
forecast
goal
intend
may
plan
possible
potential
would
words
terms
similar
meaning
drug
development
commercialization
involve
high
degree
risk
small
number
research
development
programs
result
commercialization
product
results
early
stage
clinical
trials
may
indicative
full
results
results
later
stage
larger
scale
clinical
trials
ensure
regulatory
approval
place
undue
reliance
statements
scientific
data
presented
statements
involve
risks
uncertainties
could
cause
actual
results
differ
materially
reflected
statements
including
without
limitation
occurrence
adverse
safety
events
unexpected
concerns
may
arise
additional
data
analysis
risks
unexpected
costs
delays
unexpected
concerns
may
arise
additional
data
analysis
results
obtained
clinical
trials
failure
protect
enforce
data
intellectual
property
proprietary
rights
uncertainties
relating
intellectual
property
claims
challenges
regulatory
authorities
may
require
additional
information
studies
may
fail
approve
may
delay
approval
drug
candidates
expansion
product
labeling
failure
obtain
regulatory
approvals
jurisdictions
product
liability
claims
third
party
collaboration
risks
direct
indirect
impacts
ongoing
pandemic
business
results
operations
financial
condition
foregoing
sets
forth
many
factors
could
cause
actual
results
differ
expectations
statement
investors
consider
cautionary
statement
well
risk
factors
identified
recent
annual
quarterly
report
reports
filed
securities
exchange
commission
statements
based
current
beliefs
expectations
speak
date
news
release
undertake
obligation
publicly
update
statements
whether
result
new
information
future
developments
otherwise
references
mowry
em
beheshtian
waubant
e
et
al
quality
life
multiple
sclerosis
associated
lesion
burden
brain
volume
measures
neurology
lanz
hahn
hk
hildebrandt
brain
atrophy
cognitive
impairment
multiple
sclerosis
review
published
correction
appears
j
neurol
feb
j
neurol
suppl
foley
j
xiong
k
hoyt
et
al
serum
neurofilament
light
levels
patients
multiple
sclerosis
switching
natalizumab
dosing
extended
interval
dosing
aan
butzkueven
kappos
l
spelman
et
al
significant
difference
relapse
outcomes
patients
switching
natalizumab
extended
interval
dosing
remaining
standard
interval
dosing
propensity
score
comparative
effectiveness
analysis
patients
tysabri
observational
program
ectrims
yamout
b
sahraian
ayoubi
ne
et
al
efficacy
safety
natalizumab
extended
interval
dosing
mult
scler
relat
disord
zhovtis
ryerson
l
frohman
tc
foley
j
et
al
extended
interval
dosing
natalizumab
multiple
sclerosis
j
neurol
neurosurg
psychiatry
bomprezzi
r
pawate
extended
interval
dosing
natalizumab
experience
ther
adv
neurol
disord
combined
data
based
prescriptions
clinical
trials
exposure
tecfidera
june
combined
data
based
prescriptions
clinical
trials
exposure
tysabri
july
combined
data
based
prescriptions
plegridy
march
combined
data
based
prescriptions
avonex
march
